• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 15F-12B filed by Opthea Limited

    11/20/25 4:05:18 PM ET
    $OPT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $OPT alert in real time by email
    15F-12B 1 d14142d15f12b.htm 15F-12B 15F-12B
     
     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    FORM 15F

     

     

    CERTIFICATION OF A FOREIGN PRIVATE ISSUER’S TERMINATION OF REGISTRATION

    OF A CLASS OF SECURITIES UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934

    OR ITS TERMINATION OF THE DUTY TO FILE REPORTS UNDER SECTION 13(a) OR SECTION 15(d)

    OF THE SECURITIES EXCHANGE ACT OF 1934

    Commission File Number 001-39621

     

     

    Opthea Limited

    (Exact name of Issuer as specified in its charter)

     

     

    C/- Prime Company Compliance, Level 9

    505 Little Collins Street

    Melbourne, VIC 3000

    Australia

    + 61 3 9826 0399

    (Address, including zip code, and telephone number, including area code, of registrant’s principal executive offices)

    American Depositary Shares, each representing eight ordinary shares, no par value

    Ordinary Shares, no par value*

    (Title of each class of securities covered by this Form)

     

     

     

    *

    Not for trading, but only in connection with the registration of the American Depositary Shares. Securities registered or to be registered pursuant to Section 12(g) of the Act.

    Place an X in the appropriate box(es) to indicate the provision(s) relied upon to terminate the duty to file reports

    under the Securities Exchange Act of 1934:

     

    Rule 12h-6(a) ☒    Rule 12h-6(d) ☐
    (for equity securities)    (for successor registrants)
    Rule 12h-6(c) ☐    Rule 12h-6(i) ☐
    (for debt securities)    (for prior Form 15 filers)

     

     
     


    Item 1. Exchange Act Reporting History

     

    A.

    Opthea Limited (formerly known as Circadian Technologies Limited) (the “Company” or “Opthea”) first incurred the duty to file reports under Section 13(a) or Section 15(d) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), on October 16, 2020, the date that the Company’s Registration Statement on Form F-1 relating to its ordinary shares (the “Ordinary Shares”) and American Depositary Shares (“ADSs”) was declared effective by the Securities and Exchange Commission (the “Commission”). Prior to November 20, 2025, the ADSs, each representing eight Ordinary Shares, were listed on The Nasdaq Global Select Market (“Nasdaq”). On November 10, 2025, the Company filed a Form 25 informing the Commission that the Company had determined to voluntarily delist the ADSs from Nasdaq.

     

    B.

    The Company has filed or submitted all reports required under Section 13(a) or Section 15(d) of the Exchange Act and the corresponding Commission rules for the 12 months preceding the filing of this Form 15F. The Company has filed at least one annual report under Section 13(a) of the Exchange Act.

    Item 2. Recent United States Market Activity

    The Company’s securities were last sold in the United States in a registered offering under the Securities Act of 1933, as amended, on October 21, 2020 in its initial public offering. Pursuant to a Registration Statement on Form F-1 (File No. 333-249020) originally filed with the Securities and Exchange Commission (“SEC”) on September 24, 2020 (as amended, the “Registration Statement”), the Company sold 8,563,300 ADSs, representing 68,506,400 Ordinary Shares, at an initial public offering price of US$13.50 per ADS, and pre-funded warrants to purchase 936,700 ADSs at a public offering price of US$13.49999 per pre-funded warrant.

    Item 3. Foreign Listing and Primary Trading Market

     

    A.

    The Ordinary Shares listed on the Australian Securities Exchange (“ASX”) under the symbol “OPT”, which constitutes the primary trading market for such securities.

     

    B.

    The Ordinary Shares were initially listed for trading on ASX in 1985, which listing has been maintained in excess of 12 months preceding the filing of this form.

     

    C.

    Approximately 87% of worldwide trading volume in the Ordinary Shares and ADSs, considered as a single class of securities, occurred in Australia during the 12 months from September 30, 2024 to September 30, 2025, based on trading data from the ASX and Nasdaq during such period.

    Item 4. Comparative Trading Volume Data

    Not applicable.

    Item 5. Alternative Record Holder Information

    As of October 10, 2025, there were 81 holders of record of the Ordinary Shares and ADSs, considered as a single class of securities, who were resident in the United States. In assessing the number of holders of record who are United States residents, the Company has relied on information provided by Bank of New York Mellon, the depositary for the ADSs, and MUFG Corporate Markets IT Pty Ltd.

    Item 6. Debt Securities

    Not applicable.

    Item 7. Notice Requirement

     

    A.

    As required by Rule 12h-6(h), the Company published a notice disclosing its intent to terminate its duty to file reports under section 13(a) and section 15(d) of the Exchange Act on November 20, 2025.


    B.

    The notice was disseminated in the United States by means of a press release that was posted on the Company’s website and attached as Exhibit 99.1 to the Company’s Form 6-K furnished to the SEC on November 20, 2025.

    Item 8. Prior Form 15 Filers

    Not applicable.

    PART II

    Item 9. Rule 12g3-2(b) Exemption

    The Company will publish the information required by Rule 12g3-2(b)(1)(iii), in English, on its website at www.opthea.com.

    PART III

    Item 10. Exhibits

    None.

    Item 11. Undertakings

    The undersigned issuer hereby undertakes to withdraw this Form 15F if, at any time before the effectiveness of its termination of reporting under Rule 12h-6, it has actual knowledge of information that causes it reasonably to believe that, at the time of filing the Form 15F:

     

      (1)

    The average daily trading volume of its subject class of securities in the United States exceeded 5 percent of the average daily trading volume of that class of securities on a worldwide basis for the same recent 12-month period that the issuer used for purposes of Rule 12h-6(a)(4)(i);

     

      (2)

    Its subject class of securities was held of record by 300 or more United States residents or 300 or more persons worldwide, if proceeding under Rule 12h-6(a)(4)(ii) or Rule 12h-6(c); or

     

      (3)

    It otherwise did not qualify for termination of its Exchange Act reporting obligations under Rule 12h-6.


    SIGNATURE

    Pursuant to the requirements of the Securities Exchange Act of 1934, Opthea Limited has duly authorized the undersigned person to sign on its behalf this certification on Form 15F. In so doing, Opthea Limited certifies that, as represented on this Form, it has complied with all of the conditions set forth in Rule 12h-6 for terminating its registration under Section 12(g) of the Exchange Act, or its duty to file reports under Section 13(a) or Section 15(d) of the Exchange Act, or both.

    Date: November 20, 2025

     

    OPTHEA LIMITED
    By:  

    /s/ Jeremy Levin

    Name:   Jeremy Levin
    Title:   Chief Executive Officer
    Get the next $OPT alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $OPT

    DatePrice TargetRatingAnalyst
    3/25/2025$2.00Buy → Neutral
    H.C. Wainwright
    3/25/2025$12.00 → $1.00Outperform → Market Perform
    Leerink Partners
    3/25/2025$8.00 → $1.00Buy → Underperform
    Jefferies
    3/24/2025Outperform → Perform
    Oppenheimer
    12/8/2022$14.00Buy
    H.C. Wainwright
    4/26/2022$25.00Outperform
    SVB Leerink
    More analyst ratings

    $OPT
    SEC Filings

    View All

    SEC Form 15F-12B filed by Opthea Limited

    15F-12B - Opthea Ltd (0001815620) (Filer)

    11/20/25 4:05:18 PM ET
    $OPT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 6-K filed by Opthea Limited

    6-K - Opthea Ltd (0001815620) (Filer)

    11/20/25 4:02:11 PM ET
    $OPT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 6-K filed by Opthea Limited

    6-K - Opthea Ltd (0001815620) (Filer)

    11/12/25 8:30:53 AM ET
    $OPT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $OPT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Opthea Ltd. downgraded by H.C. Wainwright with a new price target

    H.C. Wainwright downgraded Opthea Ltd. from Buy to Neutral and set a new price target of $2.00

    3/25/25 8:30:12 AM ET
    $OPT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Opthea Ltd. downgraded by Leerink Partners with a new price target

    Leerink Partners downgraded Opthea Ltd. from Outperform to Market Perform and set a new price target of $1.00 from $12.00 previously

    3/25/25 8:25:42 AM ET
    $OPT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Opthea Ltd. downgraded by Jefferies with a new price target

    Jefferies downgraded Opthea Ltd. from Buy to Underperform and set a new price target of $1.00 from $8.00 previously

    3/25/25 8:25:11 AM ET
    $OPT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $OPT
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Opthea Provides Corporate Update

    Successful DFA settlement reached Company with cash and cash equivalents of approximately USD20M Dr Fred Guerard, CEO, Tom Reilly, CFO, and Sujal Shah, Director, to step down Dr Jeremy Levin to continue as Chairman and to assume additional responsibilities as of September 1st MELBOURNE, Australia and PRINCETON, N.J., Aug. 18, 2025 (GLOBE NEWSWIRE) -- Opthea Limited (NASDAQ:OPT, "Opthea", the "Company")), today provided a corporate update following the successful settlement of the Development Funding Agreement ("DFA") with the two investors under the DFA. DFA Settlement In March of 2025, after the primary endpoints were not met in both COAST and ShORe phase 3 clinical trials, Opthea

    8/18/25 7:00:00 PM ET
    $OPT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Opthea Announces Decision to Discontinue Wet AMD Trials

    ShORe Phase 3 topline results accelerated; trial did not meet primary endpoint of mean change in BCVA from baseline to week 52 Opthea and DFA Investors agreed to terminate both COAST and ShORe trials Opthea continues to consider impact of negative trial results under its Development Funding Agreement (DFA) and on the Company as a going concern MELBOURNE, Australia and PRINCETON, N.J., March 31, 2025 (GLOBE NEWSWIRE) -- Opthea Limited (NASDAQ:OPT, "Opthea", the "Company")), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD), today announced updates on i

    3/31/25 12:01:00 AM ET
    $OPT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Opthea Announces COAST Phase 3 Trial Topline Results

    COAST Phase 3 trial failed to meet primary endpoint of mean change in BCVA from baseline to week 52 Opthea considering impact of negative trial results under its Development Funding Agreement and on the Company as a going concern MELBOURNE, Australia and PRINCETON, N.J., March 24, 2025 (GLOBE NEWSWIRE) -- Opthea Limited (NASDAQ:OPT, "Opthea", the "Company")), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD), today announced results from its global Phase 3 clinical trial COAST (Combination OPT-302 with Aflibercept Study) in patients with wet AMD

    3/24/25 12:01:00 AM ET
    $OPT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $OPT
    Financials

    Live finance-specific insights

    View All

    Opthea Announce MST Access Hosted Conference Call with Professor Jason S. Slakter, MD

    MELBOURNE, Australia, Dec. 12, 2022 (GLOBE NEWSWIRE) -- Opthea Limited ((ASX:OPT, NASDAQ:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, announce that MST Access will host an "Ask the Expert" conference call with Professor Jason S. Slakter, M.D. on Tuesday 13th December 6:30pm – 7:30pm EST USA (Wednesday 14th December 10:30am – 11:30am AEDT). Prof Slakter is a board certified Retinal and Macular Disease Specialist, Clinical Professor of Ophthalmology at New York University School of Medicine, and partner of Vitreous Retina Macula Consultants of New York. Prof Slakter will present an overview of Opthea'

    12/12/22 10:08:46 AM ET
    $OPT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $OPT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Opthea Limited

    SC 13G/A - Opthea Ltd (0001815620) (Subject)

    11/14/24 6:00:28 AM ET
    $OPT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Opthea Limited

    SC 13G/A - Opthea Ltd (0001815620) (Subject)

    7/3/24 7:15:39 PM ET
    $OPT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G/A filed by Opthea Limited (Amendment)

    SC 13G/A - Opthea Ltd (0001815620) (Subject)

    2/14/24 4:21:51 PM ET
    $OPT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $OPT
    Leadership Updates

    Live Leadership Updates

    View All

    Opthea Appoints Kathy Connell to Board of Directors

    Ms. Connell is a commercial executive with business development expertise Appointment takes place as Opthea prepares for Phase 3 wet AMD topline data in 2025 MELBOURNE, Australia, and PRINCETON, N.J., Nov. 15, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (NASDAQ:OPT, "Opthea", the "Company")), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD), today announced the appointment of Kathy Connell, GAICD, to the Board of Directors (the "Board") as a Non-Executive Director. Ms. Connell's appointment was effective immediately after the Annual General Meeting of the

    11/15/24 7:00:48 AM ET
    $OPT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Opthea Appoints Chief Medical Officer and Chief Financial Officer as Company Prepares for Phase 3 Topline Data Readouts in 2025

    Parisa Zamiri, MD, PhD, and Tom Reilly respectively appointed CMO and CFO Anand Sundaram appointed Vice President Marketing MELBOURNE, Australia and PRINCETON, N.J., Oct. 08, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (NASDAQ:OPT, "Opthea", the "Company"))), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD), today announced three senior hires as the Company continues to prepare for the sozinibercept Phase 3 topline data readouts of COAST anticipated in early Q2 calendar year 2025 and ShORe in mid calendar year 2025. "Opthea is at an inflection point with

    10/8/24 7:00:00 AM ET
    $OPT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Opthea Welcomes International Retina Thought Leaders to Join Its Medical Advisory Board

    MELBOURNE, Australia and PRINCETON, N.J., July 17, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (NASDAQ:OPT, "Opthea", the "Company"))), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD), today announces the formation of its Medical Advisory Board ("MAB") composed of 10 retina thought leaders from countries around the world including the US, Argentina, Australia, China, France, Germany, and Israel. Chaired by Arshad M. Khanani, MD, MA, FASRS, Chief Medical Advisor of Opthea, the MAB's role is to advise the Company on opportunities to address the unmet medical

    7/17/24 7:15:00 AM ET
    $OPT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care